Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4654107 | 0.79 | ALDH1A1 (0.39) | TDP1ALDH1A1HSD17B10CTSDKMT2A | |
| SCHEMBL7024449 | 0.76 | DPP4 (0.41) | ALDH1A1LMNATSHRMAPK1MTOR | |
| SCHEMBL9225010 | 0.76 | ALDH1A1 (0.36) | TDP1ALDH1A1HSD17B10CTSDKMT2A | |
| SCHEMBL2255542 | 0.70 | TDP1 (0.48) | TDP1ALDH1A1HSD17B10CTSDKMT2A | |
| SCHEMBL34463716 | 0.70 | IDO1 (0.42) | POLBTDP1ALDH1A1HSD17B10CTSD | |
| SCHEMBL942923 | 0.70 | ALDH1A1 (0.56) | POLBTDP1ALDH1A1KMT2ALMNA | |
| SCHEMBL2439065 | 0.69 | GSR (0.47) | POLBALDH1A1KMT2AL3MBTL1KLK7 | |
| SCHEMBL2439069 | 0.69 | GSR (0.47) | POLBALDH1A1KMT2AL3MBTL1KLK7 | |
| SCHEMBL14369933 | 0.69 | ALDH1A1 (0.39) | POLBTDP1ALDH1A1HSD17B10CTSD | |
| SCHEMBL943554 | 0.68 | NAPRT (0.44) | POLBALDH1A1HSD17B10KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358666-A1 | A NOVEL PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Natco Pharma Limited (IN) | 2011-08-24 | — | — | EP | disclosed |
| US-20100010022-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090203718-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LTD. (IE) | 2009-08-13 | — | — | US | disclosed |
| EP-1755394-A4 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2012587-A2 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008063853-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007121279-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070208023-A1 | Cancer Treatment Method | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| EP-1755394-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1682123-A1 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005105094-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | SMITHKLINE BEECHAM CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005046678-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2005-05-26 | — | — | WO | disclosed |
| EP-1492568-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTRATION OF AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SmithKline Beecham Corporation (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003086467-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010022-A1 | CANCER TREATMENT METHOD | TP53, TYMP, TOP2A | POLB 83/4885TDP1 806/4885ALDH1A1 965/4885 |
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | BRAF, KRAS, NRAS | POLB 2732/4885TDP1 4377/4885ALDH1A1 2591/4885 |
| US-20090203718-A1 | CANCER TREATMENT METHOD | IGF1R, EGFR, ERBB2 | POLB 829/4885TDP1 2879/4885ALDH1A1 919/4885 |
| US-20070208023-A1 | Cancer Treatment Method | TP53, TYMP, TOP2A | POLB 83/4885TDP1 806/4885ALDH1A1 965/4885 |
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | POLB 896/4885TDP1 2990/4885ALDH1A1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.